About TransCure bioServices
TransCure bioServices is a company based in Archamps (France) founded in 2012 by Patrick Nef. TransCure bioServices has raised $3.58 million across 6 funding rounds from investors including European Union, Financiere Arbevel and Cathay Capital. TransCure bioServices offers products and services including CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model. TransCure bioServices operates in a competitive market with competitors including GenOway, PsychoGenics, PharmaLegacy Laboratories, InVivo Biosystems and Noble Life Sciences, among others.
- Headquarter Archamps, France
- Founders Patrick Nef
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.58 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
European Union
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TransCure bioServices
TransCure bioServices offers a comprehensive portfolio of products and services, including CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model.
Model for human immune system in efficacy testing
For hepatotoxicity and drug evaluation studies
Combines immune and liver systems for research
Standard models for general preclinical work
Funding Insights of TransCure bioServices
TransCure bioServices has successfully raised a total of $3.58M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TransCure bioServices
TransCure bioServices has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Financiere Arbevel and Cathay Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cathay Capital is engaged in global investment and transformation.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment management services are provided for clients in Paris.
|
Locked | Locked | Locked |
Investor details for TransCure bioServices
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TransCure bioServices
Investment portfolio details for TransCure bioServices
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TransCure bioServices
Detailed financials for TransCure bioServices
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transcure Bioservices Comparisons
Peer comparison for TransCure bioServices
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TransCure bioServices
TransCure bioServices operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenOway, PsychoGenics, PharmaLegacy Laboratories, InVivo Biosystems and Noble Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of transgenic rodent models and customized cell lines for preclinical development
|
|
| Locked | Locked | Locked |
Preclinical CRO services for CNS and orphan disorders are offered.
|
|
| Locked | Locked | Locked |
Preclinical CRO offering in vivo models and services for a wide range of therapeutic areas
|
|
| Locked | Locked | Locked |
Animal models are supplied for in-vivo analytical services.
|
|
| Locked | Locked | Locked |
Preclinical contract research organization offering standard GLP and non-GLP services
|
Detailed competitors of TransCure bioServices
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transcure Bioservices
Complete news archive for TransCure bioServices
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TransCure bioServices
TransCure bioServices was founded in 2012 and raised its 1st funding round 2 years after it was founded.
TransCure bioServices is headquartered in Archamps, France. It is registered at Archamps, Haute-savoie, France.
Patrick Nef is the current CEO of TransCure bioServices. They have also founded this company.
TransCure bioServices is a funded company, having raised a total of $3.58M across 6 funding rounds to date.
TransCure bioServices was founded in 2012 in Archamps, France, within the biotechnology sector. Services are provided to pharmaceutical companies, biotechs, and academic labs using the Humanized Immune System (HIS) mouse model. This platform supports drug profiling for immune-related diseases and anti-HIVAIDS therapies. Immunodeficient mouse strains are engrafted with human CD34 hematopoietic stem cells sourced from cord blood.
TransCure bioServices's top competitors include GenOway, PsychoGenics and Alpha Genesis.
TransCure bioServices offers CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model.
TransCure bioServices has 5 investors. Key investors include European Union, Financiere Arbevel, Cathay Capital, Eurostars, and Savoie Mont Blanc Angels.